Anthem Biosciences Ltd., one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO), has launched its highly anticipated IPO. With a strong innovation-led business model and global client base, the IPO is generating considerable buzz in the pharmaceutical and biotechnology sectors.
IPO Details
-
IPO Open Dates: July 14–16, 2025
-
Issue Price Band: ₹540–₹570 per share
-
Face Value: ₹2 per share
-
Lot Size: 26 shares
-
Total Issue Size: 5.96 crore shares, aggregating up to ₹3,395 crore
-
Offer Type: Offer for Sale (OFS)
-
Listing On: BSE & NSE
-
Employee Discount: ₹50 per share
The IPO is a book-building issue with no change in the promoter’s shareholding, which remains at 74.68% post-issue, down slightly from 76.87%.
Anchor & Investor Allocation
Anthem Biosciences raised ₹1,016 crore from anchor investors on July 11, 2025. Anchor shares are under lock-in until August 16 (50%) and October 15 (remaining 50%).
Breakdown of IPO reservations:
-
QIBs: 49.87%
-
Non-Institutional Investors (NIIs): 14.96%
-
Retail Investors: 34.91% (Approx. 8 lakh applicants)
-
Employees: 0.27% with discount eligibility
Company Overview
Founded in 2006, Anthem Biosciences is a full-spectrum CRDMO offering services across drug discovery, development, and commercial manufacturing. The company specializes in fermentation-based APIs, probiotics, enzymes, biosimilars, and more. It serves over 550 global clients across 44+ countries including the U.S., Europe, and Japan.
As of September 2024, it holds eight patents (including one in India) and 24 global patent applications, highlighting its R&D strength.
Financials and Valuation
For FY 2025:
-
Revenue: ₹1,930 crore (30% YoY growth)
-
PAT: ₹451 crore (23% YoY growth)
-
EBITDA Margin: 36.81%
-
ROCE: 26.88%
-
ROE: 20.82%
-
Debt/Equity: 0.05
Market Cap: ₹31,867 crore
P/B Ratio: 13.23
Final Thoughts
Anthem Biosciences’ IPO is well-positioned to attract both institutional and retail interest. Backed by robust fundamentals, high margins, low debt, and global demand for CRDMO services, this IPO presents a compelling opportunity for long-term investors seeking exposure to India’s biotech innovation boom.
